Correction to: Nature Cancer https://doi.org/10.1038/s43018-023-00610-2. Published online 31 July 2023.
In the version of this article initially published, the description of the proteomic analysis was incorrectly termed reverse phase protein array (RPPA) instead of liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS). The Figure 3d schematic and Figure 3d,e legends as well as the Extended Data Figure 3 legend have been updated, and the Results section “The IL-17-associated cellular microenvironment in dual ICI” and Methods section “In vivo studies” have been corrected accordingly. The error does not affect the results or conclusions of this article, and we apologize for any confusion this may have caused.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Váraljai, R., Zimmer, L., Al-Matary, Y. et al. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 4, 1395 (2023). https://doi.org/10.1038/s43018-023-00632-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00632-w
